Abstract：
This study aim to assess the clinical efficacy and safety of generic cefoperazone/sulbactam compared to the branded cefoperazone/sulbactam (Sulperazon) in treating bacterial infections through a meta-analysis. Searches were conducted across PubMed, Embase, Cochrane Library, CNKI, WanFang, VIP databases, and Clinical Trials database, resulting in the inclusion of 11 studies comprising 7 randomized controlled trials (RCTs) and 4 retrospective cohort studies (RCSs). Meta-analysis of the RCTs indicated no statistical differences in clinical success rates, clinical cure rates, microbiological eradication rates, and incidence of adverse reactions between the generic cefoperazone/sulbactam and the branded version. Findings from the RCSs aligned with those from the RCTs, demonstrating that generic versions of cefoperazone/sulbactam are equivalent in efficacy and safety to their branded counterparts in treating bacterial infections.
摘要：
本研究旨在通过荟萃分析评估通用头孢哌酮/舒巴坦与品牌头孢哌酮/舒巴坦（Sulperazon）治疗细菌感染的临床疗效和安全性。搜索是在PubMed进行的，Embase,科克伦图书馆,CNKI,万方,VIP数据库,和临床试验数据库，纳入11项研究,包括7项随机对照试验(RCTs)和4项回顾性队列研究(RCSs).RCT的荟萃分析表明临床成功率没有统计学差异，临床治愈率，微生物根除率，以及普通头孢哌酮/舒巴坦和品牌版本之间的不良反应发生率。RCS的结果与RCT的结果一致，证明头孢哌酮/舒巴坦的通用版本在治疗细菌感染方面在疗效和安全性上与其品牌对应物相同。
